A Study of Mosliciguat in PH-ILD

Summary

This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Timeline

Start

2024-10-29

Primary completion

2026-12

Completion

2028-01

Outcome

Met primary endpoint

release “The PHocus study met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in PVR of -56.3%” pulmovant.com ↗

Drugs

Indications